anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A finger-nail enamel composition is obtained by mixing together components comprising 10-30 parts by weight of a film-forming base, which is a cellulose derivative or a mixture of a cellulose derivative and a resin, 10-30 parts by volume of a mixture of at least two odorous substances compounded into a perfume providing a solvent for the film-forming base, with or without a plasticizer therefor, the major portion of said mixture consisting of substances which have not less than 7 carbon atoms and at least one methyl group per molecule and are selected from the class consisting of esters, aldehydes, ketones, alcohols and essential oils, and 40-80 parts by volume of a diluent which is an aliphatic alcohol having 2-4 carbon atoms or is a propionic acid ester.  Parts by weight are expressed in relation to parts by volume in the same ratio as grams to cubic centimetres.  The cellulose derivative may be cellulose acetate or nitrate and the resin, if any, may be shellac, rosin, mastic, elemi, dammar, sandarac, kauri, ester gum or other natural or modified natural resin, or it may be a synthetic resin such as a polyvinyl, polystyrene, urea, or coumarone synthetic resin.  Specified solvent components and plasticizers are:-formic, orthoformic, acetic, propionic, butyric, sebacic, oenanthylic, pelargonic, valerianic, benzoic, salicylic, anthranilic, phenylacetic, cinnamic and like carboxylic acid esters, acetaldehyde, butyraldehyde, benzaldehyde, vanillin, heliotropin, methyl heptenone, irone, ionones, muscone, civettone, acetophenone, benzylidene acetone, methyl-b -naphthyl ketone, benzophenone, citronellol, rhodinol, geraniol, nerol, linalol, esters of terpenic alcohols, citronellal, rhodinal, citral, geranial, neral and hydroxy-citronellal.  Artificial musks, which are tert.-butyl-nitroxylenes, may be used as plasticizers.  Lavender oil, neroli oil, lemon oil, cananga oil, ylang-ylang oil and other essential oils may be used as solvents and plasticizers.  Other specified plasticizers are coumarin, acetyl isoeugenol, menthol, paracresol benzoate, benzyl cinnamate, diphenylmethane and anisic alcohol.  The diluent may be ethyl alcohol, butyl or isobutyl alcohol or isobutyl propionate.
The use of digital health solutions, especially medication reminders delivered via mHealth platforms, have shown promise as adherence support tools in sub-Saharan Africa (SSA). Importantly, the proliferation of mobile phones in resource-limited settings and the early adoption of communication technologies by young people make mHealth technologies an ideal platform for this age group. The Investigators propose to pilot a novel, mHealth peer-based intervention for AYA living with HIV in Nigeria that will utilize social and financial incentives to promote medication adherence. In addition to medication reminders and peer support, the proposed intervention will innovate within the mHealth arena to leverage the currency of social incentives through daily adherence monitoring with the provision of adherence scores for individual users in relation to their peers, and financial incentives through a monthly lottery for youth with the highest adherence scores with the prize delivered through the mHealth application itself. This proposal builds on the Investigator's successful research collaborations in Nigeria with APIN Public Health Initiatives, (APIN, a multi-site non-governmental organization with solid President's Emergency Plan For AIDS Relief-funded HIV infrastructure), the investigators expertise in building capacity for implementation research, and proficiency in developing and deploying mHealth-based interventions in SSA. This will be accomplished through the following specific aim:

To establish the feasibility, acceptability, and preliminary efficacy of PEERNaija, an mHealth intervention designed to harness peer influence as an incentive to promote medication adherence among a pilot cohort of 50 AYA living with HIV in Nigeria. Hypothesis: PEERNaija will be feasible, acceptable, and show preliminary efficacy in improving antiretroviral (ART) adherence.
AIM: To compare capabilities for diagnosing regional and global myocardial dysfunction using the values of longitudinal and circular strain, left ventricular (LV) torsion and untwisting in patients with myocardial infarction (MI) of various locations.
MATERIAL AND METHODS: Patients included in the study (n=121) were divided into three groups: patients with unstable angina (n=30), patients with anterior MI (n=45), and patients with inferior MI (n=46). Clinical, laboratory and instrumental test were performed, including echocardiography. For a quantitative analysis of LV contractility, the maximum systolic peaks of regional and global longitudinal and circular strain, systolic and diastolic rotation, LV torsion and untwisting were measured.
RESULTS: Anterior MI was characterized by injury of the LV apical segments, while inferior MI was characterized by injury of the basal segments. In anterior MI, the longitudinal strain was reduced less than 14.5% and circular strain less than 19.3% in the apical segment of the LV anteroseptal wall (ASW). In akinesia of the LV ASW apical segment, longitudinal and circular strains were reduced less than 10%. The magnitude of the circular strain of the LV ASW apical segment (diagnostic threshold 19.3%, sensitivity (Se) 87%, specificity (Sp) 90%) was superior to that of the longitudinal strain as a diagnostic marker for regional ischemic dysfunction in anterior MI. The magnitude of the circular strain of the basal segment of the LV inferior wall in inferior MI has a greater diagnostic value for identifying regional systolic dysfunction than the value of the longitudinal strain of this LV segment. The diagnostic threshold was 17.3%, Se 79%, Sp 80%.
CONCLUSION: A decrease in the circular strain of the LV ASW less than 19.3% in the LV apical segment is more specific (Sp 90%) for diagnosing regional systolic dysfunction in anterior MI than a decrease in longitudinal strain. A circular strain value of less than 17.3% in the basal segment of the LV inferior wall is more specific (Sp 80%) than the longitudinal strain of this segment for diagnosing regional systolic dysfunction in inferior MI. Predominant injury to the LV apex in anterior MI can cause systolic and diastolic myocardial dysfunction, which is manifested by a decrease in LV circular deformation, torsion and untwisting.
FIELD: medicine. SUBSTANCE: preparation for treatment of suppurative-trophic ulcers, infected wounds and decubitus in human and animals is prepared as 0.25-1% ointment. Preparation has highly active complex of proteinases "Moricrase" showing collagenolytic action on necrotic tissues. Preparation is stable at room temperature, exhibits positive effect on blood coagulation system. Ointment base - fat eiglysol shows healing action. EFFECT: enhanced effectiveness of composition.
Patients undergo apheresis over 4 hours on day 1 or course 1. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Within 36 hours after receiving pembrolizumab, patients undergo cryosurgery over 45 minutes on day 1 or 2 of courses 2 and 3. Patients also receive mature dendritic cells IT on day 1 or 2 of courses 2 and 3 after cryosurgery.
The present invention is related to a compound having excellent DGAT inhibition and ingestion inhibition or a pharmacologically acceptable salt thereof. Provided is a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof. (wherein, R1 is a hydrogen atom, a halogen atom or a carboxyl; R2 is a hydrogen atom, a halogen atom or a C1-C6 alkyl, and etc.; R3 is a hydrogen atom, a halogen atom or a C1-C6 alkyl, and etc.; T is a nitrogen atom or a group represented by the formula -CH=; W is a nitrogen atom or a group represented by the formula -CH=; U is a nitrogen atom or a group represented by the formula -CH=; V is a nitrogen atom or a group represented by the formula -CH=; Q is a nitrogen atom or a group represented by the formula -CH=; Z is a nitrogen atom, a group represented by the formula -CH=or a group represented by the formula-C(R4)=; R4 is a halogen atom or a C1-C6 alkyl, and etc.; m is 0 or 1; n is an integer of 0 to 2.
PURPOSE: An oral formulation of rapid-acting solid dispersion containing a wheat bran extract is provided to enhance dissolution in a gastrointestinal tract, and to quickly treat allergy. CONSTITUTION: An oral formulation of rapid-acting solid dispersion containing a wheat bran extract contains a solid dispersant containing the wheat bran extract and a soluble polymer as a carrier. The solid dispersant contains 0.5-300 parts by weight of the soluble polymer based on the rice bran extract. A method for manufacturing the oral formulation comprises: a step of mixing the rice bran extract, the soluble polymer, and a pharmaceutically acceptable excipient without a carrier function; and a step of spray-drying the mixture and preparing a solid dispersant. A solvent is selected from the group consisting of dichloromethane, chloroform, ethanol, methanol, acetone, isopropanol, and propanol. [Reference numerals] (AA) Concentration in blood(ng/ml); (BB) Comparative formulation; (CC) Test formulation; (DD) Time(hours)
No psychological intervention was offered. Postpartum mothers in the control condition were informed that they would receive MBCT after a waiting period of 2 months.
An aromatic amine, or a cosmetically acceptable salt thereof, is reacted with an aromatic aldehyde in a reaction medium containing water. 2,6-dihydroxypyridine, or a cosmetically acceptable salt thereof, is reacted with hydrogen peroxide in a reaction medium containing water. The two reaction mediums are combined so that both reactions are carried out together on hair. Preferably, the two reactions are carried out together in the same reaction medium. pH is adjusted so that the pH of the common reaction medium is about 5 to 7. Surprisingly, substantially no cross reaction occurs between the two reactions on hair.
Serous atrophy of bone marrow (SABM) is characterized by focal replacement of bone marrow elements with extracellular gelatinous substances. It has been associated with a wide range of chronic conditions, including anorexia nervosa, malignancy, chronic kidney disease, and certain chronic infections. Previous literature has reported the disorder as primarily diagnosed via bone marrow biopsy and occurring outside of the distal extremities. Herein we describe a case of SABM occurring in the feet diagnosed via magnetic resonance imaging (MRI), a phenomenon that is rarely reported. The patient is a 45-year-old woman with a history of end-stage renal disease, congestive heart failure, type 2 diabetes, and peripheral arterial disease who initially presented with nonhealing, bilateral foot ulcers. She subsequently underwent several podiatric medical surgeries due to persistent foot infections and poor wound healing. During her most recent hospitalization, MRIs of her feet were obtained, and findings of abnormal bone marrow signal were attributed to technical malfunction of the MRI coil or scanner. After troubleshooting sources of malfunction, a repeated MRI of the foot was obtained and again demonstrated the same bone marrow signal abnormalities; at this time, SABM was diagnosed. Knowledge of this condition can prevent the misinterpretation of SABM on MRI and prevent the waste of time and medical resources.
PURPOSE:To obtain an external drug having excellent transcutaneous absorption, by dissolving or dispersing nicardipine hydrochloride in a mixed solvent composed of a lower alcohol, lactic acid, thioglycol and urea, and compounding the solution or suspension to a base for external drug. CONSTITUTION:Nicardipine hydrochloride is dissolved or dispersed at a concentration of 1-20W/W% in a mixed solution composed of urea and one or more components selected from a 2-4C alcohol, lactic acid and thioglycol (the ratio of the components to urea is 9-1:1-9, preferably 7-3:3-7). The liquid is compounded to a base for external drug (e.g. white vaseline, plastibase, silicone oil, etc.) to obtain an external drug having cerebral vasodilating activity, coronary vasodilating activity as well as hypotensive activity. The drug has excellent transcutaneous absorbability and is applicable sufficiently as a transcutaneous drug. It can be formed in the form of ointment, tape, patch, poultice, etc.
The purposes of this educational activity were to instill in students a greater empathy for patients with intellectual developmental disabilities, give students a better understanding of how to obtain a medical history for patients with communication limitations, teach students practical tips for obtaining a medical history and physical examination to increase competence in their future practice, and to build a relationship with a local organization that serves people with intellectual disabilities. An experiential learning activity was added to the curriculum of two courses for first-year PA students to accomplish these goals. The course instructors engaged in several planning meetings with a local residential facility for people with intellectual disabilities, including choosing patients that the students would assess. The students made 3 visits to the facility. The visits included interactive lectures by a physical therapist, occupational therapist, nurse practitioner, medical doctor, and dentist. Two of the facility involved patient visits at designated homes on campus. The students then wrote comprehensive visit notes with patient identifying information removed and submitted them for grading. Students expressed feeling better prepared to assess people with intellectual disabilities and having an increased appreciation for obtaining quality medical histories. The partner facility also reported they received positive feedback from staff participants and indicated they would like to continue this partnership.
Growth hormone (GH, Somatropin, e.g. Genotropin®) is approved in the treatment of children in specific indications. However, besides the benefit in approved indications, a benefit can also be achieved in other pathological conditions that lead to growth retardation. However, because of their relative low frequency and the long duration of GH studies in children, few data or only case reports on GH treatment are available in these conditions. Nevertheless, published data have suggested a benefit of GH treatment in children suffering from some of those diseases and pediatric endocrinologists sometimes request GH treatment for those children to improve growth rate. This protocol is designed to allow such children with severe growth retardation to be treated with GH and will allow those children to be carefully followed-up and finally evaluated at the end of the GH treatment period.
Prostate cancer is among the most common malignancies found in men, with multifactorial changes occurring altogether to disrupt the pathophysiology of this gland. The Renin-Angiotensin-Aldosterone System (RAAS) is an extensively studied pathway that has newly attributed fundamental roles in cancer biology that impact cell growth, migration, metastasis, and death. These processes are significantly influenced by various components of the RAAS, including prorenin, AT1R, AT2R, and Ang 1-7/Mas receptors. Although the pathophysiology of prostate cancer is complex, targeting the RAAS shows promise as a therapeutic approach. RAAS dysregulation is evident in prostate cancer, and treatments traditionally used for cardiovascular diseases are being explored for cancer therapy. The RAAS pathway has significant effects on the formation of new blood vessels (angiogenesis), the spread of cancer cells to other parts of the body (metastasis), and cell proliferation. In this pathway, angiotensin II and its receptors have crucial functions. Angiotensin II stimulates angiogenesis and cell proliferation through the AT1R, whereas the AT2R has the opposite effect by inhibiting cell growth. Additional pathways involving ACE2/Ang 1-7/Mas also provide potential targets for therapeutic intervention, mitigating the impact of the traditional ACE/Angiotensin II/AT1R pathway. The components of the RAAS influence multiple signalling pathways, such as Androgen Receptor (AR), NF-κB, and PI3K/AKT/mTOR, which enhances our understanding of how it contributes to the progression of prostate cancer. This also provides new possibilities for therapeutic interventions.
Pregnant women in the study group were given multimedia information by watching a short video before amniocentesis and chorionic villus sampling. The multimedia information training consisted of a 5-minute video containing detailed amniocentesis and chorionic villus sampling application information. A 5-minute video was developed by the authors and used for research purposes only. The video was designed to provide pregnant women with a comprehensive overview of the amniocentesis and chorionic villus sampling procedure, its benefits, and potential risks, and included real-life images to depict all aspects of the procedure.
Process for the obtaining of 2 (1H) pyridinones and their salts of addition of acid or cationic salts, of formulas (I), in which r is hydrogen, alkyl or lower hydroxyalyllide; r is lower rent; and q and py can be various types of radicals. It consists in the reaction of a compound of formula (II), in which r and py have the same meaning as in formula (I), with N-r -alfa-cyanoacetamide. The reaction is carried out in an inert solution at the reflux temperature of the mixture. From the product obtained their derivatives can be obtained, following conventional methods. These compounds have pharmacological applications as cardiotonic agents. (Machine-translation by Google Translate, not legally binding)
BACKGROUND: Angiogenesis is associated with tumour growth, infiltration, and metastasis. This study aimed to detect the mechanisms of angiogenesis-related genes (ARGs) in multiple myeloma (MM) and to construct a new prognostic model.
METHODS: MM research foundation (MMRF)-CoMMpass cohort, GSE47552, GSE57317, and ARGs were sourced from public databases. Differentially expressed genes (DEGs) in the tumour and control cohorts in GSE47552 were determined through differential expression analysis and were enriched with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Weighted gene coexpression network analysis (WGCNA) was applied to derive modules linked to the ARG scores and obtain module genes in GSE47552. Differentially expressed ARGs (DE-ARGs) were selected for subsequent analyses by overlapping DEGs and module genes. Furthermore, prognostic genes were selected using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses. Depending on the prognostic genes, a risk model was constructed, and risk scores were determined. Moreover, MM samples from MMRF-CoMMpass were sorted into high- and low-risk teams on account of the median risk score. Additionally, correlations among clinical characteristics, gene set variation analysis (GSVA), gene set enrichment analysis (GSEA), immune analysis, immunotherapy predictions and the mRNA‒miRNA‒lncRNA network were carried out.
RESULTS: A total of 898 DEGs, 211 module genes, 24 DE-ARGs and three prognostic genes (AKAP12, C11orf80 and EMP1) were selected for this study. Enrichment analysis revealed that the DEGs were related to 86 GO terms, such as 'cytoplasmic translation', and 41 KEGG pathways, such as 'small cell lung cancer'. A prognostic gene-based risk model was created in MMRF-CoMMpass and confirmed with the GSE57317 dataset. Moreover, a nomogram was established on the basis of independent prognostic factors that have proven to be good predictors. In addition, the immune cell infiltration results suggested that memory B cells were enriched in the high-risk group and that immature B cells were enriched in the low-risk group. Finally, the mRNA‒miRNA‒lncRNA network demonstrated that hsa-miR-508-5p was tightly associated with EMP1 and AKAP12. RT‒qPCR was used to validate the expression of the genes associated with prognosis.
CONCLUSION: A new prognostic model of MM associated with ARGs was created and validated, providing a new perspective for exploring the connection between ARGs and MM.
Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient. Rarely, allergic-type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance. 

To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions.
Artificial intelligence integrating multiple layers of clinical information such as clinical examination, signs/symptoms and medical history, and laboratory information such as outcomes of biomarkers (CRP and WBC) and pathogen specific POCT (malaria and bacterial infections) and oximetry will be developed. The e-algorithm will serve to guide the diagnostic and management of febrile infections in children from 2 to 59 months.
PURPOSE: A pharmaceutical composition containing telmisartan is provided to maintain dissolution rate, to enhance stability compared with a conventional telmisartan tablet, and to ensure easy packaging such as a PE bottle and PTP packaging. CONSTITUTION: A pharmaceutical composition contains telmisartan and magnesium aluminometasilicate. Telmisartan is adsorbed to magnesium aluminometasilicate. The weight ratio of telmisartan and magnesium aluminometasilicate is 1:0.2-1. The pharmaceutical composition further contains tromethamol. A method for manufacturing a telmisartan formulation comprises a step of adsorbing telmisartan to magnesium aluminometasilicate. [Reference numerals] (AA) Example 1; (BB) Comparative example 1
The skin will first be properly cleaned with rubbing alcohol. An I-shaped strip of Kinesio tape with a 5-cm width was applied over the middle trapezius from origin to insertion in the KT group. Kinesio-tape size was measured from the T3 spinal process to the acromion, while the subject is in sitting position relaxed with the arm at the trunk side. The subject was then instructed to move the arm into horizontal adduction and neck flexion. At this position, the tape was applied involving the middle trapezius, ending on the acromion, with 50% tension as recommended for this technique.
A wide variety of topical vehicles are available for medications that treat scalp disorders. Proper vehicle selection is important when managing scalp conditions, such as seborrheic dermatitis, because the efficacy of these treatments depends largely on compliance and the amount of active ingredient delivered to the scalp. It is therefore important to prescribe vehicles that are easy to apply and cause the least amount of disruption to the patients' pre-existing hair care practices. One of the most common rate limiting hair care practices among different cultures is wash frequency. Literature shows African American women are more likely to wash their hair less than once weekly versus Caucasian women. We hypothesize certain vehicles, such as foam preparations which do not require hair washing, will be more efficacious in African American women with seborrheic dermatitis than shampoo preparations.